vimarsana.com

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab for G/GEJ Cancer at ASCO 2024

BioPharma

Related Keywords

China ,Suzhou ,Jiangsu , ,Transcenta Holding Limited ,Holding Limited ,Clinical Oncology Volume ,

vimarsana.com © 2020. All Rights Reserved.